Rare diseases
Investigational molecules
Locations
117 Kendrick Street Suite 500, 02494-2730, United States
Verastem Inc. supports clinical research in non-small cell lung cancer with a focus on targeted treatment strategies for tumors carrying G12C alterations. The sponsor’s studies examine combinations centered on avutometinib and sotorasib in patients with advanced lung cancer.
The research activity reflects sustained interest in molecularly defined thoracic oncology and treatment options for KRAS G12C-mutant disease.
Verastem Inc. runs clinical trials in conditions such as Ovarian cancer, Malignant mast cell neoplasm, Colorectal adenocarcinoma, Ovarian cancer recurrent, among others.
Clinical trials run by this sponsor – those enrolling participants first.
Phase 1/2 Study of VS-7375 with Drug Combination in Patients with Advanced KRAS G12D‑Mutated Solid Tumors
BelgiumStudy Comparing Avutometinib and Defactinib with Other Treatments for Patients with Recurrent Low-Grade Serous Ovarian Cancer
BelgiumA Phase 2 Study of VS-7375 Alone or with Drug Combination in Patients with Metastatic KRAS G12D‑Mutated Colorectal Cancer
BelgiumOpen‑Label Extension Study of Avutometinib Alone or with Defactinib in Patients with Recurrent Low‑Grade Serous Ovarian Cancer
FranceStudy of Avutometinib and Defactinib for Patients with Recurrent Low-Grade Serous Ovarian Cancer
BelgiumStudy of Avutometinib, Sotorasib, and Defactinib for Patients with KRAS G12C Mutant Non-Small Cell Lung Cancer
BelgiumIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
